Provided by Tiger Fintech (Singapore) Pte. Ltd.

Applied Therapeutics Inc.

0.4349
+0.02486.05%
Post-market: 0.4300-0.0049-1.13%17:20 EDT
Volume:6.23M
Turnover:2.66M
Market Cap:50.60M
PE:-0.30
High:0.4504
Open:0.4100
Low:0.4000
Close:0.4101
Loading ...

Company Profile

Company Name:
Applied Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
37
Office Location:
545 Fifth Avenue,Suite 1400,New York,New York,United States
Zip Code:
10017
Fax:
- -
Introduction:
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States. Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Directors

Name
Position
Shoshana Shendelman
President, Chief Executive Officer and Chair of the Board of Director
Franklin M. Berger
Director
Jay S. Skyler
Director
Joel S. Marcus
Director
Les Funtleyder
Director
Stacy J. Kanter
Director
Teena Lerner
Director

Shareholders

Name
Position
Shoshana Shendelman
President, Chief Executive Officer and Chair of the Board of Director
Mark J. Vignola
Chief Financial Officer
Riccardo Perfetti
Chief Medical Officer